---
schema_version: "secwatch.filing_event.v1"
accession: "0001376339-25-000044"
form_type: "8-K"
ticker: "MDXG"
cik: "0001376339"
company_name: "MIMEDX GROUP, INC."
filed_at: "2025-04-30T23:59:59+00:00"
generated_at: "2026-05-23T02:09:10.064767+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.65
calibrated_materiality_score: 0.65
confidence: "high"
source: SEC EDGAR
---

# MiMedx Q1 net sales $88M (+4% YoY); GAAP EPS $0.05; reaffirms high single-digit growth outlook

## Summary
- Net sales $88M (+4% YoY); GAAP net income $7M ($0.05 EPS); Adj. EBITDA $17M (20% margin).
- Gross margin fell to 81% from 85% on product mix; Surgical products grew 16%, Wound fell 2%.
- Cash $106M; net debt $0; 2025 outlook: high single-digit sales growth and >20% Adj. EBITDA margin.
- CEO calls LCD delay disappointing; added CELERA product as contingency for affected settings.
- SG&A rose to $60M from $55M on higher commissions, salaries, and legal/regulatory costs.

## SEC filing metadata
- accession: 0001376339-25-000044
- form_type: 8-K
- ticker: MDXG
- cik: 0001376339
- company_name: MIMEDX GROUP, INC.
- filed_at: 2025-04-30T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.65
- calibrated_materiality_score: 0.65
- confidence: high
- sec_items: 2.02, 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1376339/000137633925000044/0001376339-25-000044-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1376339/000137633925000044/mdxg-20250430.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001376339-25-000044
- JSON: https://secwatch.observer/filing/0001376339-25-000044.json
- Plain text: https://secwatch.observer/filing/0001376339-25-000044.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.